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Abstract
Background: Recreational diving occurs annually in areas of the world where malaria is endemic. The safety and
efficacy of antimalarials for travelers in a hyperbaric environment is unknown. Of particular concern would be
medications with adverse effects that could either mimic diving related illnesses such as barotrauma,
decompression sickness (DCS) and gas toxicities, or increase the risk for such illnesses.
Methods: We conducted a review of PubMed and Cochrane databases to determine rates of neurologic adverse
effects or other effects from antimalarials that may be a problem in the diving environment.
Results: One case report was found on diving and mefloquine. Multiple case reports and clinical trials were found
describing neurologic adverse effects of the major chemoprophylactic medications atovaquone/proguanil,
chloroquine, doxycycline, mefloquine, and primaquine.
Conclusions: Of the available literature, atovaquone/proguanil and doxycycline are most likely the safest agents
and should be preferred; atovaquone/proguanil is superior due to reduced rates of sunburn in the marine
environment. Primaquine also appears to be safe, but has reduced efficacy against P. falciparum; mefloquine
possesses the highest rate of neurologic side effects and therefore these agents should be limited to extreme cases
of patients intolerant to other agents. Chloroquine appears unsafe in the hyperbaric environment and should be
avoided. More studies are required to include database reviews of returned divers traveling to malaria endemic
areas and randomized controlled trials in the hyperbaric environments.
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Background
Recreational Diving with a self-contained underwater
breathing apparatus (SCUBA) is a popular hobby.
Authors cite there are between 1 and 3 million [1, 2]
to 5–9 million [3, 4] persons in the United States and
another 90 thousand [2] to 1 million [1] persons in
the UK or Europe, respectively, participating actively
in Scuba Diving. While figures are hard to come by,
one trade source estimated that the sport diving
industry generated approximately $3.5 billion in in-
come for equipment suppliers and retailers, course
instructors and certification agencies and travel and
tourism operators worldwide in 1994 [5]. Due to the
large number of participants and the high value to the
travel and tourism industry, travel medicine professionals
need to be cognizant of this constituency and how to opti-
mally manage their pre-travel care, particularly if they are
traveling to malaria endemic regions.
Hazards inherent to sport diving
“Diving is not dangerous until you forget that it can be”
[6]. This quote from the memoirs of a retired North Sea
diver sum up the risks of diving nicely; for while the
underwater hyperbaric environment poses risks to the
diver such as barotrauma, decompression sickness
(DCS), hypothermia, drowning and marine animal
envenomation, as long as one maintains attention to
detail and continuously monitors one’s equipment and
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environment, the risk of injury is generally very low. The
Divers Alert Network reports approximately 90 fatalities
a year [4], mostly from drowning [1], and 900–1000
persons requiring hyperbaric treatment for decompres-
sion illness [4]. A recent workshop concluded the death
rate to be about 0.7 per 100,000 dives and an individual
risk per annum of 1in 6000 which was similar to motor
vehicle operation or jogging [7]. Unlike driving a motor
vehicle or jogging however, the diver has to contend not
only with the external environment but also the internal
effects arising from the physiologic changes related to
pressure exposure. Some of these effects are well known
and can be managed, such as direct insult to air filled
cavities via barotrauma, DCS from the build-up of inert
gas in the tissues and the direct narcotic effects of nitro-
gen on the central nervous system at depth. However,
little is known about how the concomitant use of medi-
cations affect the diver while under pressure either
directly via changes in cognition for instance or indir-
ectly by affecting their risk for DCS or nitrogen narcosis.
Furthermore, as more technologically advanced equip-
ment and gas mixtures (with their own potentially toxic
effects) become available to the recreational diver, the
margin for error decreases and thus the potential risk
for adverse outcomes increases when medication is
added to the mix. For instance, oxygen is often used at
higher concentrations than that in compressed air to
increase time at depth, but comes with the risk of
depth-dependent toxicity on both the lungs and more
acutely, the risk of central neurologic toxicity, including
seizure. Thus a drug that affects seizure threshold may
increase the risk of such at depth.
Because of this, many diving physicians will not clear a
person for participation in SCUBA diving if they are
taking medications with neurocognitive side effects.
Furthermore, divers who receive these medications are
usually told not to continue diving while taking them.
Generally, taking medications while diving is discouraged
but not necessarily prohibited due to the lack of clinical
studies on safety in the hyperbaric environment, and
considerations of the risk/benefit associated with the
underlying disease that is being managed. Interestingly, a
cross-sectional survey of medication usage in Australian
and US divers shed some light on this issue. The authors
reported 3–10 % of experienced divers routinely used
decongestants, anti-emetics or bronchodilators within 2 h
prior to diving, furthermore 25 % of divers were on
chronic medications despite no safety data to endorse
these practices [8].
In his pioneering work on diving physiology in the
1960s, Bennett studied the effect of several drugs on
DCS [9] in rats. Carbachol (cholinergic agonist), gluteth-
imide (an anticonvulsant), phenacetin (an analgesic), epi-
nephrine, scopolamine, pentylenetetrazol, and bemegride
(stimulants), all increased incidence of death or spinal
cord DCS in these animals. Unfortunately, there are very
few human studies on the safety of some medications in
diving. Dimenhydrinate, an antihistamine with known
sedating side effects induced reduced cognitive capabil-
ities as tested drawing a trail between numbered circles
at 10 and 30 meters of sea water (msw) in a hyperbaric
chamber, but 5 other cognition tests showed no im-
pairment [10]. On the other hand, both clemastine,
another CNS active antihistamine, and pseudoephed-
rine had no effect on subjects in a hyperbaric environ-
ment, demonstrating that some medications are indeed
safe to use [11, 12].
In addition to the neurologic side effects, SCUBA diving
also alters cardiovascular physiology due to immersion
and relative hypothermia, both of which cause central
shunting and peripheral vasoconstriction that would alter
volume of distribution and consequently renal clearance
and hepatic redistribution rates [13, 14]. Depending on
pharmacokinetics, these changes could therefore affect
both the efficacy and side effect profile of a medication,
and reciprocally a drug could alter these physiologic
responses by changing tissue gas dynamics and thus risks
for DCS and toxic effects of pressurized breathing gases.
Because diving related illnesses require management by a
specialist and often recompression in a chamber, both of
which may be hours away by automobile or aircraft, diag-
nostic decisions confounded by medications could delay
therapy or unnecessarily utilize resources, putting the
patient at undue risk of a medevac if an incorrect diagno-
sis of a diving illness is made.
Risks of malaria to the diver
Due to great underwater visibility, temperature and the
colorful variety of marine life encountered, tropical
destinations are popular and among the most highly
visited by divers [2]. Invariably, these destinations will
include countries where malaria is endemic, indeed a
2012 trade publication cited countries such as Honduras,
Indonesia, the Philippines, Malaysia, Thailand as among
the “top 100 readers choice” places to go diving. Diving
vacations are usually conducted from either shore based
resorts which has shore diving or transports the divers
out to the dive site in a boat. The majority of these
shallow dive sites therefore are close to land and poten-
tially place the diver at risk of malaria acquisition if they
are diving in an endemic area. Alternatively, there are
“live-aboard” vessels constructed or modified specifically
to house diving operations during the day and berth the
divers at night. Live aboard boats should not be assumed
to be safe from malaria transmission however. Radio
labeled Anopheles spp. mosquitoes have been shown to
fly 2 miles in studies [15] suggesting that any diver on
shore or on board a boat is at risk for malaria and
Petersen and Regis Tropical Diseases, Travel Medicine and Vaccines  (2016) 2:23 Page 2 of 8
therefore should be given counseling on prevention if
diving in a country where malaria is endemic.
Review of antimalarial agents
The most effective protective measure against malaria is
the use of oral prophylactic anti-malarial drugs taken prior
to exposure. This is particularly true where topical pre-
ventative agents like DEET and permethrin-impregnated
clothing are not an option due to the periodic immersion
in seawater. The safety of oral antimalarials in diving how-
ever is unknown and they have not been evaluated in
humans or animals [16]. Given the concerns about altered
physiology and side effects of medications in a hyperbaric
environment, a review of the available literature is desper-
ately needed. A review of PUBMED articles using the
keywords “diving” and “malaria” resulted in only 1 article,
a letter to the editor advocating the avoidance of meflo-
quine and adoption of doxycycline as the preferred anti-
malarial in diving [17, 18]. Indeed, a table from another
publication indicates an absence of existing studies [16].
We will therefore review the side effects of various anti-
malarials with a focus on ones that could possibly mimic
symptoms of barotrauma, DCS or gas toxicity; or alterna-
tively, affect the diver’s risk thereof. A search was con-
ducted of PUBMED and Cochrane databases using the
keywords atovaquone, proguanil, chloroquine, prima-
quine, mefloquine, doxycycline, chemoprophylaxis, mal-
aria, adverse effect, side effect, neurologic, psychiatric,
neurocognitive and central nervous system.
Chloroquine
Chloroquine has long been used for both the prevention
and treatment of malaria. Unfortunately, due to wide-
spread use for over three quarters of a century, its effect-
iveness as a malaria prophylactic is limited to just a few
areas of the world, many of which are popular diving
destinations. It is, however, still used worldwide in
conjunction with proguanil for prophylaxis in chloro-
quine resistant areas as a cost effective alternative to
some of the more expensive antimalarial medications,
demonstrating a 72 % (95 % CI: 56 to 82 %) effectiveness
in a 1993 study with similar findings in more recent
studies [19–21]. Furthermore, it is used for diseases
other than malaria, including the management of rheu-
matologic disorders and treatment of amebiasis [22, 23].
Conversely, hydroxychloroquine sulfate, a drug primarily
used for treatment of rheumatologic conditions can be
used in place of chloroquine [24]. For the prevention of
malaria, chloroquine is generally initiated with or with-
out proguanil 1–2 weeks prior to travel and continued
for 4 weeks upon return [24]. It is taken once weekly,
making it convenient for long term use. Because it is
one of the older antimalarials, its side effect profile is
one of the better known and studied.
The more commonly reported side effects include gastro-
intestinal disturbance, headache, dizziness, blurred vision,
insomnia, and pruritus; all are generally mild and normally
do not require discontinuation of the drug [19, 24]. In a
multicenter, randomized, double blind study of non-
immune travelers to sub-Saharan Africa, the chloroquine-
proguanil (C-P) arm had the highest proportion of mild to
moderate adverse events (69/153; 45 %, 95 % CI: 37 to
53 %) but only 8 withdrawals from the group of 153
(5 %, 95 % CI: 2 to 9 %). This was not statistically
different (p = 0.425) from the other treatment arms
which included atovaquone-proguanil (A-P) (n = 3; 2 %,
95 % CI: 0 to 4 %), mefloquine (n = 6; 4 %, 95 % CI: 1 to
8 %) and doxycycline (n = 5; 3 %, 95 % CI: 0 to 6 %)
[19]. These numbers were similar to earlier studies [21]
and although manageable, as demonstrated by the low with-
drawal rate, these symptoms could be confused with DCS.
Also, while many of the symptoms may manifest during the
pre-travel/diving period and thus be dealt with accordingly,
others may not present until diving has commenced. Fur-
thermore, besides being DCS confounders they may
certainly affect a diver’s performance and could lead to a
diving mishap if they are not managed appropriately.
Though rare but of legitimate concern, are the much
more severe neuro-psychiatric side effects attributed to
chloroquine. Severe symptoms of headache, strange or
vivid dreams, dizziness, anxiety, depression, sleepless-
ness, and visual disturbance were noted to be 4 % (95 %
CI: 1–7 %) in one study, while a population-based obser-
vational study using a database of 35,370 patients
showed an incidence rate for depression, psychosis and
panic attacks to be 7.6 % (95 % CI 5.5–10.5), 0.4 (95 %
CI 0.1–1.6) and 1.3 % (95 % CI 0.6–2.8), respectively [19,
25]. Furthermore, numerous cases of seizures have been
reported in patients receiving chloroquine in varying
doses for both prophylaxis and treatment of malaria and
other disorders with good demonstration of cause and
effect [21, 26–28]. The mechanism is thought to be re-
lated to the inhibition of GABAergic neurotransmission
[28]. This is particularly concerning as there is some evi-
dence that this pathway is involved in the mechanism by
which the neuroleptic vigabatrin prevents the seizures
associated with hyperbaric oxygen toxicity. This suggests
that chloroquine could possibly lower the seizure thresh-
old in divers, particularly those diving oxygen enriched
mixtures such as Nitrox [29]. It is because of this seizure
risk that many militaries avoid prescribing this medica-
tion to its divers deploying to malaria endemic areas.
While its low cost and relatively tolerable side effect
profile make it an attractive option for the general popu-
lation, the myriad of mild to severe adverse effects that
both mimic and possibly potentiate the spectrum of
illnesses that could afflict a diver prohibit its prescription
in this population.
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Mefloquine
Mefloquine is a readily available medication worldwide
and is available as a generic making it a cost effective
choice for prophylaxis; it is generally started 2 weeks
prior to travel. Mefloquine’s once weekly dosing sched-
ule make it a convenient agent for those on long term
trips to the tropics, such as expatriates and military
forces on deployment where adherence can be an issue.
In addition, it is not photosensitizing (an advantage to
patients in a mostly marine or beach environment) and
does not cause gastric irritation. However, the drug has
well established central nervous system side effects esti-
mated between 1/607 and 20,000 patients [16], manifes-
tations that could be mistaken for DCS or arterial-gas-
embolism-related neurological symptoms in a diver [17].
This could result in subsequent inappropriate hyperbaric
treatment and or aeromedical evacuation, hence the
author’s recommendation against its use in sport divers
at risk for malaria acquisition [18]. Initial studies in over
600 travelers to Africa quoted a 10 % adverse neuro-
psychiatric side effect rate, with 17 % described as mod-
erate and 4 % as severe. A recent study of more than
1,000 Peace Corps volunteers taking malaria prophylaxis
over a 1-year period showed 65 % had some neuro-
psychiatric side effect (23 % mild, 31 % moderate and
10 % severe) requiring 35 % to seek medical care, 1 % to
be hospitalized and 28 % to change prophylaxis regimens
[30]. However, most diving trips are not for prolonged
periods of time and the relatively unique isolation expe-
rienced by Peace Corps volunteers immersed in a foreign
culture may introduce psychosocial stressor bias in-
applicable to dive travel. In a head-to-head trial against
chloroquine, mefloquine caused significantly higher rates
of vivid dreams, depression, dizziness, nausea, irritability
and tremor. Neuropsychiatric adverse events occurred
between 5 and 10 % of subjects [31]. In a trial comparing
mefloquine to doxycycline, there were higher rates of
headache, vertigo and neuropsychiatric events in the
mefloquine arm [32]. Finally, in comparison with atova-
quone/proguanil, a study of 1013 patients in 15 travel
clinics showed the rate of all described neuropsychiatric
side effects was twice as common (29 % vs 14 %) in
patients using mefloquine prophylaxis, and 19 (4 %) of
patients had to discontinue therapy in the mefloquine
arm versus only 3 (0.6 %) in the atovaquone/proguanil
arm [33]. However, in tests of complex flying or driving
performance using simulators, there was no significant
psychomotor impairment even when coupled with etha-
nol, suggesting that side effects may be milder and more
tolerable than reported and the drug may have a safe pro-
file for diving [34, 35]. Unfortunately, Mefloquine has a
United States Food and Drug Administration, Australian
Therapeutic Goods Administration and United Kingdom
Medicines and Healthcare products Regulatory Agency
“black box” (or country equivalent) warning included in
the package inserts stating that the risk of vestibular and
neuropsychiatric adverse reactions may persist indefinitely
and all patients must receive a medication guide and
wallet card with their prescription. This warning and
potential risk for litigation has diminished provider enthu-
siasm to prescribe this medication in the United States.
In summary, Mefloquine has the highest rates of
CNS side effects of all prophylactic anti-malarial med-
ications occurring in 10 to 30 % of patients and thus
should be a last option for diving vacations where
prophylaxis is required due to its potential to mimic
dysbaric symptoms. However, certain patients prepar-
ing for dive travel to a malarious area may be a can-
didate for use if they are intolerant of all other anti-
malarial medications. Especially if there is the oppor-
tunity for a trial dose and observation for side effects
prior to travel, with strict instructions to discontinue
the medication at first sign of adverse events.
Doxycycline
Doxycycline is has been in clinical use for almost half a
century for both its antimicrobial properties as well as
its anti-inflammatory ones. Its uses include the manage-
ment of soft tissue infections, atypical bacterial infec-
tions and malaria, as well as acne vulgaris and rosacea
where sub-therapeutic doses are thought to control the
inflammatory component of the disease [36–38] al-
though all these indications require a higher dose than
malaria prophylaxis. Like chloroquine, its low cost
makes it an attractive anti-malarial prophylactic and be-
cause of its proven effectiveness as a prophylactic, it is
listed as one of the accepted alternatives for such [36].
In addition, it is convenient for last minute travelers as
it is started only a few days before travel, and may
already be prescribed in the same doses for acne. It
would also prevent other infections that an adventurous
traveler, like a diver, may come in contact with, including
leptospirosis and rickettsial infections. Disadvantages are
its requirement for daily dosing as well as its toxicities
in certain populations such as pregnant women and chil-
dren under 8 years old. Furthermore, its side effect pro-
file, though not generally prohibitive to its use (even in
divers), requires proper counseling to the traveler to
assure both proper measures are taken to mitigate their
likelihood as well as self-monitoring for their onset to
ensure prompt and appropriate management.
The list of all possible side effects for doxycycline is
quite long and the reader is directed elsewhere to the
numerous drug reference sources available for a compre-
hensive list. The focus here will be on those that could
be confused with DCS or place the diver at risk for such,
ranging from the common related to gastrointestinal
tract and skin to the rarer and more idiosyncratic which
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affect the central nervous system. Nausea (13 %) and
vomiting (8 %) are among the more commonly reported
side effects and while protean, can certainly be a pre-
senting sign of the more constitutional DCS symptoms
[39]. Fortunately these can be mitigated by avoiding
administration on an empty stomach and assuring ad-
equate hydration [39]. The latter precaution is also im-
portant because the tablets should be taken with plenty
of water and not before bedtime, i.e. well prior to laying
down, to avoid the pill esophagitis commonly associated
with doxycycline and whose symptoms could be mis-
taken for a diving induced pneumomediastinum, par-
ticularly if there is either an esophageal ulcer or
perforation present [38]. It should be further noted that
there are different formulations of doxycycline and while
there have been no direct comparisons of the different
forms in clinical trials there is some evidence that the
hyclate salt form causes more gastrointestinal side ef-
fects than the monohydrate or enteric coated hyclate
formulation presumably due to its higher acidity [40].
Thus, selected prescribing of particular salt formulations
along with proper patient education on administration
could have a considerable effect on lowering the inci-
dence of gastrointestinal side effects.
Photosensitivity is another commonly associated effect
of doxycycline administration with rates between 3 and
10.7 % and manifestations ranging from mild papular
erythema to exfoliative dermatitides [39, 41, 42]. This
has been shown to be dependent both on the dose as
well as the intensity of sunlight exposure [41, 43]. This
is a particular problem for recreational divers in that
cutaneous DCS can present similarly and diving often
occurs in tropical environments where there is constant
exposure to heat and bright sunlight, posing the di-
lemma of staying covered versus the risk of overheating
and dehydration. While liberal and frequent use of
appropriate sunblock can mitigate this effect it is no
guarantee with severe dermatitis having been reported
even with adequate sunblock use [42]. The one helpful
delineator between cutaneous DCS and doxycycline
phototoxicity is the predilection of the latter for sun-
exposed areas and the former for a truncal distribution.
Finally, doxycycline has neurological side effects ranging
from the more common headache (2 %) and dizziness to
the rarer but concerning intracranial hypertension and
its associated symptoms, which all can mimic the more
severe neurological presentation of DCS [38, 39]. While
tetracycline is more commonly implicated with the latter
side effect it has been described with doxycycline to
include those taking it for malaria prophylaxis [44–47].
Fortunately, the incidence for all idiopathic intracranial
hypertension is rare with estimates in the United States
being 0.9 per 100,000 persons/year, making this an
uncommon but noteworthy side effect in the diver for
whom doxycycline is being considered [48]. A study of
22 rabbits under hyperbaric conditions demonstrated a
76 % increase in Blood Brain Barrier permeability and
higher CSF levels for tetracycline than controls, clearly
showing that diving alone affects pharmacology. There
was no statistical difference in DCS rates (7 DCS vs. 9 No
DCS) among rabbits with elevated brain antibiotic levels,
but this is a very underpowered study to comment on the
safety of doxycycline in diving and it did not address
oxygen toxicity [49].
In summary, while doxycycline is a recommended
second line agent for malaria prophylaxis due to its cost,
effectiveness and short period of pre-travel dosing, its
side effect profile, though manageable, keeps it in the
alternate category for the traveling diver as well.
Atovaquone/proguanil
Atovaquone/proguanil (A-P) is available in many coun-
tries as a co-formulated tablet for both adult and pediatric
patients. It appears to be very well tolerated with minimal
side effects, however it must be taken daily starting 2 days
prior to travel and continued on a daily basis throughout
the trip and for a week afterwards; it is also quite costly.
In a double blind placebo controlled efficacy and toxicity
study of more than 1000 patients conducted in 21 travel
clinics in Europe, Canada and South Africa, A-P was com-
pared to chloroquine plus proguanil and adverse events
were monitored at day 7 and 28 after leaving a malarious
region [21]. Twenty-two percent of participants reported
adverse effects from A-P with half being gastrointestinal
and the other half (10 %) neuropsychiatric; the majority of
these side effects were mild. Strange or vivid dreams were
most common in among neuropsychiatric side effects
(4 %), followed by dizziness (3 %) and visual difficulties
(2 %), but no neuropsychiatric side effect appeared more
common than chloroquine/proguanil with statistical sig-
nificance and none required stopping the medication.
Only 11 persons (10 in the C-P and one in the entire A-P
arm) discontinued medication due to drug attributable
side effects (A-P drug allergy not neuropsychiatric).
A-P was also evaluated in a randomized double blind, pla-
cebo controlled trial compared to mefloquine among 1000
patients presenting to travel clinics in Europe and South
Africa [33]. Patients received mefloquine placebo followed
by active A-P or active mefloquine followed by A-P placebo;
the mefloquine was started 3 weeks before travel and the A-
P 2 days before and continued for 30 or 7 days after return,
respectively. Thirty percent of patients in the A-P arm had
drug attributable side effects, and of those 14 % were neuro-
psychiatric, with the majority being strange dreams (7 %),
insomnia (3 %) and dizziness (2 %). Adverse effects were
significantly less common (2–4 fold) than mefloquine how-
ever, and only 3 of 493 persons in the entire trial receiving
A-P had to discontinue drug due to adverse effects. The
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investigators believed the higher rate of neuropsychiatric
side effects observed compared to the previous trial
against C-P was attributable to mefloquine placebo effect
as symptoms often appeared prior to active A-P use.
A third trial conducted in a travel clinic in the
Netherlands again randomized 140 patients to meflo-
quine placebo plus A-P or A-P placebo plus mefloquine
[50]. One hundred nineteen patients completed the
study and all patients were screened repeatedly with 2
mood index tools. There were no changes noted in ten-
sion, depression, anger, fatigue or vigor from baseline in
patients taking A-P. This was a marked contrast to
patients in the mefloquine arm who experienced signifi-
cant deterioration in depression, fatigue, anger and vigor.
Concentration skills such as hand eye coordination or
coding speed were not affected by either medication.
Finally, a Canadian study of A-P vs. primaquine in 28
pilots revealed no significant impact on neurocognitive
testing like serial reaction, subtraction, or logical reasoning
and no impact on flight simulator performance [51]. There
was also no increase in physical fatigue, sleepiness, or
mental fatigue. Overall, A-P has one of the lowest neuro-
psychiatric side effect profiles ranging between 10 and
14 % in 2 large trials, and has other side effects that are
generally gastrointestinal in nature, although most patients
report all side effects as mild and none required discon-
tinuation for neurological intolerability. The rate of side ef-
fects may be overstated in these initial trials however, due
to mefloquine placebo bias and drug approval symptom
recording methods as no adverse effects were detected in
subsequent intensive mood index and neurocognitive
trials. Because of its relatively low side effect profile, espe-
cially those that could mimic or potentiate a diving related
illness, A-P is considered a preferred option for diving
travel to malarious regions ahead of all other agents.
Primaquine
Primaquine is an 8-aminoquinoline anti-malarial devel-
oped for treatment of P. vivax or P. ovale malaria to pre-
vent relapse. It is now being studied as a gametocytocidal
agent in P. falciparum eradication efforts. In addition, it
has been studied as primary prophylaxis against both P.
falciparum and P. vivax malaria where it has showed an
85–93 % protective efficacy [52, 53]. These studies re-
sulted in Primaquine’s inclusion as an recommended alter-
native agent for malaria chemoprophylaxis [24], however
it is not approved for this use by regulatory agencies and
must be used “off-label” The dosing however, has the
highest pill burden of all prophylaxis at 2 pills a day
started 2 days before travel and continued for a week after
returning. In a Canadian study of primaquine vs A-P,
neurocognitive impact in 28 pilots revealed no significant
impact on neurocognitive testing like serial reaction,
subtraction, or logical reasoning and no impact on flight
simulator performance. There was also no incidence of
sleepiness, mental fatigue, or physical fatigue [51].
Observed side effects included abdominal cramps, head-
ache, nausea and diarrhea. All symptoms predominated in
the first week, often improved subsequently, and were
mild in nature. Other sources suggest GI side effects are
mild and can be minimized or eliminated by taking the
medication with food [24]. The sole incidence of CNS side
effects from primaquine described in the literature is a
case report of a 55 y/o male who developed depression,
anorexia, confusion, auditory hallucinations, 2 days after
starting 15 mg of primaquine; the symptoms resolved 24 h
after discontinuing medication [54]. Overall, primaquine’s
low side effect profile and the relative lack of CNS side
effects make it an attractive option for diving travel, how-
ever its relatively lower protective efficacy against malaria
and higher pill burden relegate it to a second line option
compared to other agents.
Conclusions
Table 1 contains a summary of recommended prophy-
laxis for dive related travel to malaria infected regions; it
Table 1 Antimalarial Prophylaxis Recommendations for Dive
Related Travel
Prophylactic medication Recommendation Comments
Atovaquone-proguanil
250/100 mg daily
Primary regimen • Lowest and most
benign side effect profile
Doxycycline
100 mg daily
Secondary regimen • Phototoxicity and
esophageal effects
make second line





Alternative regimen • Lower level of
protective efficacy than
other agents
• High pill burden
Mefloquine
250 mg weekly
Alternative regimen • Prophylaxis of last
resort
• High levels of CNS side
effects may mimic DCS
• Possibility with test









• Known association with
seizures
• Theoretical possibility of
eliciting hyperbaric
oxygen seizure
• Other CNS side effects
Petersen and Regis Tropical Diseases, Travel Medicine and Vaccines  (2016) 2:23 Page 6 of 8
should be noted that the level of evidence is low around
CII for most chemoprophylactic agents. Based on avail-
able evidence and knowledge of diving physiology, it is
our opinion the preferred regimen to prevent malaria in
this group of travelers is atovaquone-proguanil due to its
low side effects profile and high protective efficacy
against P falciparum malaria. Doxycycline as an accept-
able alternative, assuming proper counseling and precau-
tions, and would be equivalent except for its rare side
effect of intracranial hypertension and its propensity to
photosensitization, especially in the marine environment.
Furthermore, because atovaquone-proguanil and doxy-
cycline are both currently used by the U.S. Navy aviation
community and are considered to not affect cognitive
function in pilots, they are logical candidate drugs for
diving operations as well. However, the daily dosing
schedule can decrease adherence, possibly causing
breakthrough cases of malaria. In patients intolerant or
allergic to these 2 agents, Primaquine is a good alterna-
tive due to its lack of neurocognitive side effects, but it
has a higher pill burden and lower efficacy than A-P or
doxycycline against falciparum malaria. Mefloquine is
the drug of last resort due to its impact on sleep, mood
and neurologic side effects, however since it does not
appear to impact psychomotor function and many
patients do not get side effects it could be used in the
rare patient intolerant to all other agents, provided test
doses are given and the patient observed for side effects
prior to travel. Chloroquine should not be used due to
its risk to induce seizures. For all chemoprophylactic
agents, safety in relation to oxygen toxicity or DCS
remains a huge unanswered question with limited stud-
ies available for review. Clearly the paucity of data in this
realm calls for more research.
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